Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the Standard Comparator of Minimally Invasive Surgical Therapies (MIST) for Benign Prostatic Obstruction? Medical Versus Surgical Treatment.

European urology·2026
Same author

Comparative 30-day life cycle assessment of bladder drainage strategies.

BJU international·2026
Same author

Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

European urology·2026
Same author

Evaluation and management of transient lower urinary tract symptoms (LUTS) after surgery for Benign prostatic obstruction (BPO): a systematic review.

Prostate cancer and prostatic diseases·2026
Same author

"EASY Study": A European, Prospective, Postmarket, Single-arm Study of Altis Single-incision Mini-sling for Female Stress Urinary Incontinence.

European urology focus·2026
Same author

Impact of new decrees on pelvic implant surgery in France: Results of a national survey among urologists and gynecologists.

The French journal of urology·2026

Related Experiment Video

Updated: Jul 10, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

[Recent progress in basic research concerning the management of benign prostatic hyperplasia].

Jean-Nicolas Cornu1, Morgan Rouprêt

  • 1Service d'Urologie de l'Hôpital Pitié-Salpêtrière, Paris, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|November 1, 2007
PubMed
Summary

Phosphodiesterase type 5 (PDE-5) inhibitors show promise for treating benign prostatic hyperplasia (BPH) and related lower urinary tract symptoms (LUTS). These agents relax prostatic cells, potentially offering a new therapeutic avenue, especially when combined with alpha1-blockers.

More Related Videos

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jul 10, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Area of Science:

  • Pharmacology
  • Urology

Context:

  • Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
  • Current BPH treatments primarily focus on managing LUTS.
  • Phosphodiesterase type 5 (PDE-5) inhibitors are emerging as potential therapeutic targets.

Purpose:

  • To investigate the pharmacological mechanisms of PDE-5 inhibitors in BPH.
  • To evaluate the effects of PDE-5 inhibitors on detrusor and prostatic muscle cell contraction.
  • To explore the potential of PDE-5 inhibitors as a future treatment for LUTS in BPH.

Summary:

  • PDE-5 inhibitors demonstrate efficacy in reducing prostatic cell contraction in vitro.
  • These effects are dose-dependent and are enhanced when combined with alpha1-blockers.
  • The mechanism involves modulating detrusor and prostatic muscle cell relaxation.

Impact:

  • PDE-5 inhibitors represent a novel therapeutic strategy for BPH-related LUTS.
  • Combination therapy with alpha1-blockers may offer improved treatment outcomes.
  • Further research could establish PDE-5 inhibitors as a valuable addition to BPH management.